Kazia Therapeutics Ltd's (ASX:KZA) James Garner speaks to Proactive's Andrew Scott soon after announcing they've executed a definitive agreement with the Global Coalition for Adaptive Research (GCAR) to begin participation in the GBM AGILE pivotal study in glioblastoma. The study is set to open a new arm with Kazia’s investigational new drug, paxalisib, and will now move into an operational phase with recruitment of patients to the paxalisib arm expected to begin in the first quarter of 2021.